Astellas is doubling down on gene therapy while others retreat. Richard Wilson, SVP Primary Focus Lead, Genetic Regulation at Astellas, joins In Vivo to discuss why the company believes AAV technology will transform medicine despite current industry headwinds. 🎯 Key Topics: - Why Astellas opened a massive new gene therapy manufacturing facility - Building an end-to-end AAV platform from research to commercial - Strategic partnerships driving CNS and rare disease programs - Maintaining team morale in a challenging investment climate - Regulatory outlook and the path to commercial success Richard also plays a role in Astellas' West Coast Innovation Center and serves on the Alliance for Regenerative Medicine board. He shares insights on manufacturing at scale, patient-centric culture, and the long-term potential of gene therapy. Perfect for biotech investors, pharma executives, and anyone tracking the evolution of genetic medicines. 🔗 More insights: insights.citeline.com/in-vivo

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related